Pernix signs agreement with Osmotica Pharmaceutical Corp to promote Khedezla (Desvenlafaxine ER) tablets for Major Depressive Disord

28-02-2014 Business Wire HealthComments (0)

Pernix TherapeuticsUSA

Pernix Therapeutics Holdings (NASDAQ GM: PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced that it has signed an agreement with Osmotica Pharmaceuticals Corp (“Osmotica”) to market and sell KHEDEZLA™ (desvenlafaxine) Extended-Release (ER) Tablets, 50 mg and 100 mg. The sales and marketing of KHEDEZLA will be supported by Pernix’s team of approximately 90 sales professionals, promoting the product to high desvenlafaxine prescrib

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top